Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
This study is investigating a new medication, lenacapavir, for individuals living with HIV-1 infection. It's specifically for those whose current HIV treatments are no longer working effectively due to the virus becoming resistant to multiple medicines. The main goal is to find out if adding lenacapavir to their existing treatment for a short period can help lower the amount of HIV in their body. Researchers will also look at how safe the new drug is and how well it works over a longer time when combined with other effective HIV medicines. This is an important step towards finding new options for people with complex HIV-1 infection.
نظرة سريعة
النتائج
نتائج هذه الدراسة
تم النشر October 2021تم نشر نتائج هذه الدراسة.
ما هو موضوع هذه الدراسة؟
This study is looking at a new medicine called lenacapavir, designed for people living with HIV-1. HIV, or human immunodeficiency virus, is a condition that affects your immune system. While there are many effective treatments for HIV, some people find that over time, the virus changes and becomes resistant to the medicines they are taking. This means their current treatments might stop working as well as they used to.
The study aims to help people who are in this situation – those whose HIV has become resistant to several different types of medication. The researchers want to see if adding lenacapavir to their current treatment can help reduce the amount of HIV in their body. This process will happen in two main stages: first, they'll check how well lenacapavir works on its own for a short time, and then they'll see how it performs when combined with other effective HIV medicines.
Finding new treatment options is really important for people with multi-drug resistant HIV, as it can be challenging to manage their condition. This study hopes to provide data that could eventually lead to new ways to help people keep their HIV under control and improve their overall health.
النقاط الرئيسية
- This study is for people with HIV-1 whose current treatments are not fully effective.
- It tests a new medicine, lenacapavir, for multi-drug resistant HIV.
- Participation involves taking new medicine (pills and injections) and regular doctor visits.
- You might receive a placebo initially, but everyone eventually receives the new drug.
- The study aims to find new ways to treat complex HIV infections.
من قد يكون مؤهلاً؟
To join this study, you would generally need to be at least 18 years old. In some parts of the world, like North America, teenagers aged 12 and above who weigh at least 35 kg might also be able to join. You need to have been on an HIV treatment for more than 8 weeks that isn't currently working well for you, meaning your blood test shows a certain level of HIV in your body.
Additionally, your HIV must show signs of resistance to several different types of existing HIV medications. This means your doctors would confirm that your HIV is difficult to treat with many standard drugs. You should also not have an ongoing Hepatitis C infection at the time of screening.
Your doctor will be able to check all these details to see if you meet the full requirements for taking part in this study.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you aged 18 or over (or 12-17 and at least 35kg in some regions)?
- Is your current HIV medicine not fully controlling your virus?
- Has your doctor told you your HIV is resistant to several different treatments?
- Do you not have an active Hepatitis C infection?
- Are you able and willing to take new medicines as directed?
- Could you attend regular hospital visits for check-ups and tests?
ماذا يتضمن المشاركة؟
If you join this study, you might receive either the new medicine, lenacapavir, or a dummy pill (placebo) for a short period, in addition to your current HIV treatment. After this initial stage, all participants will receive lenacapavir along with a new combination of HIV medicines chosen by your doctors that are expected to work well for you. This will involve taking pills by mouth and also receiving some injections under the skin. You'll have regular hospital visits, blood tests, and check-ups to monitor your health, how the medicine is affecting your HIV, and to look for any side effects. The total duration of your involvement in the study will be explained in detail by the study team.
المخاطر والفوائد المحتملة
Locations (75)
- Ruane Clinical Research Group Incالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Mills Clinical Researchالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Eisenhower Health Center at Rimrockالرمز البريدي المؤكدPalm Springs, United States
- One Community Healthالرمز البريدي المؤكدساكرامنتو، الولايات المتحدة
- Yale University; School of Medicineالرمز البريدي المؤكدنيو هيفن، الولايات المتحدة
- Washington Health Instituteالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة
- Midland Florida Clinical Research Center, LLCالرمز البريدي المؤكدDeLand, United States
- Gary J. Richmond, M.D., P.A.الرمز البريدي المؤكدفورت لودرديل، الولايات المتحدة
- Midway Immunology and Research Centerالرمز البريدي المؤكدFt. Pierce, United States
- Floridian Clinical Researchالرمز البريدي المؤكدهياليه، الولايات المتحدة
- AIDS Healthcare Foundation - South Beachالرمز البريدي المؤكدميامي بيتش، الولايات المتحدة
- Orlando Immunology Centerالرمز البريدي المؤكدأورلاندو، الولايات المتحدة
أسئلة شائعة
What is multidrug resistance (MDR) in HIV?
Multidrug resistance means that the HIV in your body has changed and become resistant to several different types of HIV medicines, making your current treatments less effective.
What is an 'Optimized Background Regimen' (OBR)?
An OBR is a new combination of existing HIV medicines chosen by your doctor that are expected to work well for you, even if your HIV has some resistance.
هل سأعرف إذا كنت أحصل على الدواء الفعال أم دواء وهمي؟
Initially, it's possible you might get a placebo, and you won't know which one you're receiving. However, after a short period, all participants will receive the active study medicine, lenacapavir.
How is lenacapavir given?
Lenacapavir will be given as a tablet you take by mouth and also as an injection under your skin.
Can I stop taking part in the study at any time?
Yes, your participation is completely voluntary, and you can decide to stop taking part at any time without it affecting your future medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.